Eiger Biopharmaceuticals Inc., a start-up seeking to develop a cure for chronic hepatitis delta virus (HDV), is on the verge of closing a series B financing that will help it advance its lead candidate, lonafarnib, while also broadening its portfolio to include multiple phase II, orphan-designated programs.